IBDEI0EH ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6606,0)
 ;;=446.6^^31^412^119
 ;;^UTILITY(U,$J,358.3,6606,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6606,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,6606,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,6606,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,6607,0)
 ;;=286.4^^31^412^122
 ;;^UTILITY(U,$J,358.3,6607,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6607,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,6607,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,6607,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,6608,0)
 ;;=204.00^^31^412^1
 ;;^UTILITY(U,$J,358.3,6608,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6608,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,6608,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,6608,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,6609,0)
 ;;=204.01^^31^412^2
 ;;^UTILITY(U,$J,358.3,6609,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6609,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,6609,1,5,0)
 ;;=5^ALL,In Remission
 ;;^UTILITY(U,$J,358.3,6609,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,6610,0)
 ;;=204.10^^31^412^13
 ;;^UTILITY(U,$J,358.3,6610,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6610,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,6610,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,6610,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,6611,0)
 ;;=204.11^^31^412^14
 ;;^UTILITY(U,$J,358.3,6611,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6611,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,6611,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,6611,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,6612,0)
 ;;=201.90^^31^412^80
 ;;^UTILITY(U,$J,358.3,6612,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6612,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,6612,1,5,0)
 ;;=5^Hodgkin's Lymphoma,Unspec Type/Site
 ;;^UTILITY(U,$J,358.3,6612,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,6613,0)
 ;;=785.6^^31^412^87
 ;;^UTILITY(U,$J,358.3,6613,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6613,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,6613,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,6613,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,6614,0)
 ;;=200.20^^31^412^89
 ;;^UTILITY(U,$J,358.3,6614,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6614,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,6614,1,5,0)
 ;;=5^Lymphoma, Burkitt's, Unspecified Sites
 ;;^UTILITY(U,$J,358.3,6614,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,6615,0)
 ;;=202.00^^31^412^91
 ;;^UTILITY(U,$J,358.3,6615,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6615,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,6615,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,6615,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,6616,0)
 ;;=200.10^^31^412^90
 ;;^UTILITY(U,$J,358.3,6616,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6616,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,6616,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,6616,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,6617,0)
 ;;=273.3^^31^412^92
 ;;^UTILITY(U,$J,358.3,6617,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6617,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,6617,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,6617,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,6618,0)
 ;;=203.00^^31^412^104
 ;;^UTILITY(U,$J,358.3,6618,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6618,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,6618,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,6618,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,6619,0)
 ;;=203.01^^31^412^103
 ;;^UTILITY(U,$J,358.3,6619,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6619,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,6619,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;
 ;;$END ROU IBDEI0EH
